New antibody drug takes on Hard-to-Treat cancers

NCT ID NCT06999187

Recruiting now Disease control Sponsor: Dren Bio Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called DR-0202, a bispecific antibody, in people with advanced solid tumors (such as breast, lung, and pancreatic cancers) that have not responded to at least two prior treatments. The study aims to find a safe dose and see if the drug shows any anti-cancer activity. About 96 participants will receive multiple doses of DR-0202, and researchers will monitor side effects closely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DR-0202 (a bispecific antibody)
What this could lead to: If successful, this could point toward a new treatment option for several advanced cancers that have stopped responding to standard therapies.
What could go wrong: This is an early Phase 1 trial with only 96 participants, so the drug may not prove safe or effective. Side effects are unknown, and the study is not designed to confirm benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATE RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma cervical cancer endometrial cancer endometrium neoplasm gastric cancer gastric neoplasm gastroesophageal cancer gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma Her2-receptor negative breast cancer non-small cell lung carcinoma ovarian cancer pancreatic ductal adenocarcinoma Squamous Cell Carcinoma of Head and Neck transitional cell carcinoma triple-negative breast carcinoma urothelial carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATE RESISTANT PROSTATE CANCER CERVICAL CANCER ENDOMETRIAL CANCER GASTRIC CANCER GASTROESOPHAGEAL JUNCTION CANCER HEAD AND NECK SQUAMOUS CELL CARCINOMA HER2-NEGATIVE BREAST CANCER NON-SMALL CELL LUNG CANCER OVARIAN CANCER PANCREATIC DUCTAL ADENOCARCINOMA TRIPLE NEGATIVE BREAST CANCER UROTHELIAL CARCINOMA

Contacts and locations

Locations

Dren Investigational Site
RECRUITING

Denver, Colorado, 80218, United States
Dren Investigational Site
RECRUITING

Orlando, Florida, 32827, United States
Dren Investigational Site
RECRUITING

Sarasota, Florida, 34232, United States
Dren Investigational Site
RECRUITING

Huntersville, North Carolina, 28078, United States
Dren Investigational Site
RECRUITING

Oklahoma City, Oklahoma, 73104, United States
Dren Investigational Site
RECRUITING

Greenville, South Carolina, 29605, United States
Dren Investigational Site
RECRUITING

Austin, Texas, 78758, United States
Dren Investigational Site
RECRUITING

Dallas, Texas, 75230, United States
Dren Investigational Site
RECRUITING

San Antonio, Texas, 78229, United States
Dren Investigational Site
RECRUITING

Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.